Koninklijke Philips NV

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0000009538
EUR
22.74
-0.3 (-1.3%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Koninklijke Philips NV stock-summary
stock-summary
Koninklijke Philips NV
Pharmaceuticals & Biotechnology
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Company Coordinates stock-summary
Company Details
Breitner Center, Amstelplein 2 , AMSTERDAM None : 1096 BC
stock-summary
Tel: 31 20 597777731 31 205977222
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jeroen van der Veer
Independent Chairman of the Supervisory Board
Ms. Christine Poon
Independent Vice Chairman of the Supervisory Board, Secretary
Ms. Neelam Dhawan
Independent Member of the Supervisory Board
Ms. Orit Gadiesh
Independent Member of the Supervisory Board
Mr. A. Marc Harrison
Independent Member of the Supervisory Board
Mr. David Pyott
Independent Member of the Supervisory Board
Dr. Paulus Stoffels
Independent Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4,097 Million
(Quarterly Results - Mar 2025)
Net Profit:
78 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 22,792 Million ()

stock-summary
P/E

209.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

17.32%

stock-summary
Debt Equity

0.37

stock-summary
Return on Equity

1.51%

stock-summary
Price to Book

2.16